“Oncolytic Virotherapy in Melanoma Treatment: A Breakthrough Approach”
Melanoma has long challenged oncologists due to its aggressive nature and ability to spread quickly. Oncolytic virotherapy has emerged as a breakthrough for many melanoma patients, especially those who do not respond well to conventional treatments. The first FDA-approved oncolytic virus, based on herpes simplex virus, was specifically designed to target melanoma cells. Once injected directly into the tumor, the virus replicates and causes tumor destruction while simultaneously activating the immune system.
This therapy also supports the use of immune checkpoint inhibitors, creating a synergistic effect that allows the body to fight melanoma more effectively. Patients often experience shrinking tumors, better symptom control, and improved quality of life. As research progresses, virotherapy is expected to expand into early-stage melanoma treatment and potentially prevent recurrence by training the immune system to stay alert.
FAQ
1. Why is virotherapy effective in melanoma?
Melanoma cells are susceptible to viral infection and immune recognition.
2. How is it given?
Usually by direct injection into the tumor.
3. Can it prevent recurrence?
It may reduce recurrence risk by boosting immune memory.
4. Does it replace immunotherapy?
No, but it enhances immunotherapy response.
5. Are side effects severe?
Most are mild and include injection-site discomfort.